DAFTAR PUSTAKA
Ahmed HG, Al-Adhraei MA, Al-Thobhani AK.(2011) Correlation of Hormone Receptors (ER and PR), Her2/neu and p53 Expression in Breast Ductal Carcinoma Among Yemeni Women. The Open Cancer Immunology Jounal. 4,1-9
American Cancer Society, (2013). Breast Cancer Fact & Figures 2013-2014.
Asako O, Takaharab S, Sumiyoshia K, Yamamotoa H, Kawaic J andShibaa E (2013) Relationship between intrinsic subtypes and tumor responses to neoadjuvant chemotherapy in patients with locally advanced breast cancer.Breast Disease 34 (2012/2013) 9-17
Azim Jr HA, Partridge AH, (2014) Review :Biology of Breast Cancer in Young Women. Breast Cancer Research 16:427:p1-9
Baziad A. (2008). Endokrinologi Ginekologi edisi ketiga: Menopause.Penerbit Media Aesculapius Fakultas Kedokteran Universitas Indonesia. Hal.115-117.
Berstadt, P, Coates R J, Bernsteins L, Folger S G, Malone K E, Marchbanks P A, et al (2010). A Case Control Studyof Body Mass Index and Breast Cancer Risk in White and African- American Women. Cancer Epidemiologic
Biomarkes, 1532-1544.
Brufsky AM, (2011).Understanding the estrogen receptor signaling pathway focus on current endocrine agents for breast cancer in postmenopausal women (review). Community Oncology;8:343-52.
Byrd DR, Edge SB (2010) AJCC Breast Cancer Staging Manual, 7th Ed. New York. NY: Springer.p347-76
Dahlan MS, (2013) Besar Sampel dan Cara Pengambilan Sampel edisi 3, Penerbit Salemba Medika
Departemen Kesehatan Republik Indonesia, (2013) Pemerintah Targetkan 80% Perempuan dapat Deteksi Dini Kanker Payudara dan Kanker Serviks.
Devita VT, Hellman S, Rosenberg SA.(2008) Penyunting. Cancer Principles and practice of oncology. Edisi ke-8. Philadelphia. Lippincott william & Wilkins.
Dillon D, Guidi AJ, Schnitt SJ. (2014) Pathology of Invasive Breast Cancer. In Disease of the Breast. 5th ed. Haris JR, Lippoman ME, Morrow M, Osborne CK( editors). Wolters Klumer Health. p381-410
Dowsett M, Miller W. (2014) Estrogen and Progesterone Receptor Testing for Prognosis and Prediction. In Disease of the Breast. 5th ed. Haris JR, Lippoman ME, Morrow M, Osborne CK( editors). Wolters Klumer Health.p411-22
Dunwald LK, Rossing MA, Li CI. (2007) Breast Cancer Researh. Hormon receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.
Ellis IO, Schinitt SJ, Satre GX, (2003) Invasive Breast Carcinoma in World Health Organization Classification of Tumours Pathology & Genetics Tumours of Breast and Female Genital Organs. IARC; 13-59
Fabian CJ, Kivoler BF (2005). Selective Estrogen Receptor Modulator for Primary Prevention of Breat Cancer. J. Clinical Oncology.p.1644-55
Globocan, (2012) Breast Cancer Incidence and Mortality Worldwide in 2012 Summary.
Ghiasvand R, Adami HO, Harirchi I, Akrami R, Zendehdel K. (2014) Higher Incidence of Premenopausal Breast Cancer in Less DevelopedCountries ; Myth or Ruth? BMC Cancer 14: 343;p1-8
Hammond MEH, Daniel F, Hayes, Dowsett M, Allerd DC, Karen L et al (2010) American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Journal of Clinical Oncology. Volume 28 16:2784-2792
Pakistani Patients. Asian Pacific Journal of Cancer Prevention 14: 4353-4357
Huang,W.,Newman, B., Millikan, R., Schell, M., Hulka,B., & Moorman,P.(2000) Hormone-related Factors and Risk of Breast Cancer in Relation to Estrogen Receptor and Progesterone Receptor Status. American Journal of
Epidemiology, 703-714.
Kardinal CG.( 2002) Hormonal and Endocrine Therapy of Breast Cancer. In Cancer of the Breast. 5th Ed. Donegan WL, Spratt JS (Editors). Saunders.p693-726
Kartika EPI,Maulani H, Sulastri H, Yuwono.(2009) Ekspresi Protein Her-2/net, Status Reseptor Estrogen dan Progesteron pada berbagai Derajat Keganasan Karsinoma Payudara Duktal Invasif Wanita Usia Muda. Majalah Patologi Vol. 18 No.1:p32-41
Kuiper GG, Enmark E, Pelto-Huiko M, Nilsson S, Gustafsson JA. (1996) Cloning of a Novel Receptor Expressed in Rat Prostate and Ovary. Proc.Nattl. Acad. Sci. USA, 93(12):p5925-30
Lari SA and Kuerer HM, (2011) Review: Biological Markers in DCIS and Risk of Breast Recurrence: A Systemetic Review. Journal of Cancer 2; 232-61 Levin ER,(2005), Integration of Extranuclear and Nuclear Actions of Estrogen.
Mol. Endrocrinologi. 19(8):p1951-9
Payne SJL, Bowen RL, Jones JL & Wells CA. (2008) Predictive markers in breast cancer- the present histopatholgy;52: 82-90
Petricevic J, Petkovic M, Jonjic N. (2011) Expression of Estrogen and Progesterone Receptors in Human Ductal Invasive Breast Carcinoma Not Otherwise Specified : Is there any Difference Between Premenoausal and Postmenopausal Women?. Acta Clin Croat; 50: 169-175
Rajan G, Culas TC, Jayalakshmy PS.(2014) Estrogen and Progesterone Receptor Status of 450 Women in Kerala, South India. World Journal of surgical Oncology.12:120 p1-4
Rosai J. (2004). Breast. In Rosai and Aekerman’s Surgical Pathology, 9th Ed. Philadelphia: Elsevier,p.1763-1877
Rumah Sakit Umum Pendidikan H.Adam Malik Medan, (2012) Data Kasus
Keganasan Payudara 2008-2011. [Unpublished].
Shanaz N. Profil Hormonal Reseptor pada Pemeriksaan Immunohistokimia pada Pasien Kanker Payudara di RSUD dr. Soetomo pada tahun 2009.Fakultas Kedokteran Universitas Airlangga. Surabaya 2010
Suyatno, Pasaribu ET, (2014) Bedah Onkologi; Diagnosis dan terapi, edisi ke-2. Seagung Seto. Jakarta.
Talley LI, Grizzle WE, Waterbor JW, Brown D, Weiss H, Frost AR. (2002) Hormone Receptors and Proliferation in Breast Carcinomas of Equivalent Histologic in Pre- and Postmenopausal Women. Int. J. Cancer: 98, p118-127
Vasei M, Azarpira N, Talei A.(2006) Status of Estrogen and Progesterone Receptors in Various Phases of the Menstrual Cycle in Breast Cancer. Archive of Iranian Medicine, volume 9(3):250-253
Viale G, Regan MM, Mastropasqua MG, Maiorano E, Colleoni M, Price KN et al (2008). Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst. 100:207-212
Yanger JD, Davidson NE.(2006). Mechanisms of disease, Estrogen Carcinogenesis in Breast Cancer. New England Journal of Medicine; 354:270-82
Yanagawa M, Ikemot K, Kawauchi S, Furuya T, Yamamoto S, Oka M, et al (2012). Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumor with different genotype. BMC Reasearch Notes 5:376;p1-8
Weigel MT and Dowsett M, (2010) Review; Current and emerging biomarkers in breast cancer: prognosis and prediction; Endocrine- Related Cancer .17:R245-R262
